News Releases

News & Resources

News Releases

Synteract Experts Sharing Insights on Drug Development Topics at US and European Biopharma Events During Fall 2015

SAN DIEGO – September 10, 2015 – Synteract will present and exhibit at several events this fall both in the US and in Europe: Outsourcing in Clinical Trials New England in Boston, the annual joint DIA/EFGCP/EMA Better Medicines for Children Conference in London, and Outsourcing in Clinical Trials Southern California in San Diego. The company’s senior leadership team will be in attendance to discuss current issues within the clinical research industry, including considerations required for global clinical trials as well as challenges facing pediatric drug development.

At OCT New England, Sept. 16-17, 2015, Synteract will exhibit at booth #38. Dan Cormican, associate director of project management, will discuss “Planning for Global Clinical Trials: Benefits, Challenges and Solutions” on Wednesday, Sept. 16 at 4:45 p.m. His presentation will cover selecting countries based on assessment of disease incidence, factoring in standard of care and protocol compliance, understanding the role of feasibility studies, and more. Because Synteract has conducted Phase I-IV studies on six continents and in more than 60 countries, the team is well-versed in running efficient and effective global clinical trials.

From October 1-2, EMA pediatric drug development experts will meet to discuss long-term solutions for addressing pediatric needs in the drug development process at the Better Medicines for Children Conference. Dr. Martine Dehlinger-Kremer, global vice president, medical and regulatory affairs, will be part of the panel discussion on Thursday, Oct. 1 at 4:00 p.m., titled, “Looking Back at the 10 Years of the Pediatric Legislation – the Ways Forward.” On Friday, Oct. 2 at 11:00 a.m., she will present “The CRO’s Perspective on Feasibility and Challenges with Pediatric Clinical Trials.” Dehlinger-Kremer is a member of the European CRO Federation program committee and has been chair of the Pediatric Working Group of EUCROF since 2008. She is also a member of the European Network of Pediatric Research at the European Medicines Agency Working Groups. Earlier this year, she was named one of the 2015 PharmaVOICE 100 “Most Inspiring People in Life Sciences.”

Attendees who would like to schedule an appointment with Synteract at OCT New England may contact Megan O’Keefe, senior business development director at 917-692-8047. Those interested in scheduling an appointment at the Better Medicines for Children Conference may contact Sebastien Duval, vice president of business development Europe, at +33 6 01 61 21 81. For live updates during the events, follow Synteract on LinkedIn and Twitter.

About Synteract                                                    
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies. Synteract has conducted Phase I-IV studies on six continents and in more than 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, Synteract provides customized services collaboratively and cost effectively to provide “Tomorrow’s Treatments” to the patients who need them.

# # #

CONTACT:
Amanda Whitlock
amanda@clearpointagency.com
760-230-2424

x

Contact Synteract

Tell us how to stay in touch with you:

*Required